Investing.com UK - Financial Markets Worldwide
Open in App

K Pharma Inc (4896)

Tokyo
Currency in JPY
750.00
-50.00(-6.25%)
Closed·
Advertisement

K Pharma (4896) Income Statement & Profits

Period Ending:
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
Total Revenues
--1,000--
Total Revenues Growth
-----
Cost Of Revenues
--90--
Gross Profit
--910--
Gross Profit Growth
-----
Gross Profit Margin %
--91%--
Other Operating Expenses, Total
219353543836916
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
-+61.19%+53.82%+53.96%+9.57%
--255451414
219353259380482
--29520
Operating Income
-219-353367-836-916
Operating Income Growth
--61.19%+203.97%-327.79%-9.57%
EBIT Margin %
--36.7%--
Net Interest Expenses
-----4
Net Interest Expenses Growth
-----
Interest Expense, Total
-----7
Interest And Investment Income
----3
Other Non Operating Expenses, Total
-1-7-24-1-2
EBT, Excl. Unusual Items
-220-360343-837-922
Gain (Loss) On Sale Of Assets
-8-31---
Other Unusual Items, Total
---43-7-69
EBT, Incl. Unusual Items
-228-391300-844-991
EBT, Incl. Unusual Items Growth
--71.49%+176.73%-381.33%-17.42%
EBT, Incl. Unusual Items Margin
--30%--
Income Tax Expense
-14022
Net Income to Company
-228-392260-846-993
Minority Interest
-----
Net Income
-228-392260-846-993
Net Income Growth
--71.93%+166.33%-425.38%-17.38%
Net Income Margin %
--26%--
Preferred Dividend and Other Adjustments
-----
Net Income to Common Excl. Extra Items
-228-392260-846-993
Basic EPS - Continuing Operations
-30-42.0125.39-72.9-85.57
Basic EPS - Continuing Operations Growth
--40.06%+160.44%-387.1%-17.37%
Diluted EPS - Continuing Operations
-30-42.0123.07-72.9-85.57
Diluted EPS - Continuing Operations Growth
--40.06%+154.91%-416%-17.37%
Basic Weighted Average Shares Outstanding
7.69.3310.2411.611.6
Diluted Weighted Average Shares Outstanding
7.69.3311.2711.611.6
Dividend Per Share
-----
Dividend Per Share Growth
-----
EBITDA
-----
EBITDA Growth
-----
EBITDA Margin %
-----
EBIT
-219-353367-836-916
* In Millions of JPY (except for per share items)

FAQ

What was K Pharma’s net income for the year?

For the last full fiscal year, K Pharma reported net income of -993.00 million JPY.

How much net income did K Pharma post in the last quarter?

In the most recent quarter, K Pharma (4896) posted net income of -242.00 million JPY.

What was K Pharma’s annual operating income?

For the latest full fiscal year, K Pharma (4896) reported operating income of -916.00 million JPY.

What was K Pharma’s operating income last quarter?

Quarterly operating income was -234.00 million JPY.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.